BackgroundThis review aimed to address the question of whether cognitive impairment
should be considered a core feature of depression that may be a valuable target for …

Major depressive disorder is a common condition with a high rate of recurrence, chronicity,
and staggering economic burden, including disability in the workforce. 1 In 2010, MDD was …

Objective The primary objective of this review is to examine the literature assessing
abnormalities in neural circuitry and cognition early in the course of major depressive …

Objective: Neurocognitive deficits are demonstrated in major depressive disorder (MDD)
and most likely contribute to the functional impairment experienced by affected individuals …

Major depressive disorder (MDD) is a prevalent and recurring mental disorder often
associated with high rates of non-recovery and substantial consequences on psychosocial …

Monoamine-based treatments for depression have evolved greatly over the past several
years, but shortcomings such as suboptimal efficacy, treatment lag, and residual cognitive …

Major depressive disorder (MDD) is associated with cognitive dysfunction encompassing
several domains, including memory, executive function, processing speed and attention …

Pharmacological treatments for depression have insufficient efficacy in 30–40% of patients
and fail to reverse cognitive deficits. Erythropoietin (EPO) has neurotrophic actions and aids …

Background Major depressive disorder is associated with very high recurrence rates, and
specific vulnerability factors that increase the risk for repeated episodes should be identified …

Cognitive dysfunction is increasingly recognized as a symptom in mental conditions
including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BPD) …